See the DrugPatentWatch profile for pradaxa
The generic name for Pradaxa is dabigatran etexilate [1][2]. Dabigatran etexilate is an oral anticoagulant medication [1].
What is dabigatran etexilate used for?
Dabigatran etexilate is used to prevent blood clots in adults who have had a certain type of stroke or a condition called atrial fibrillation [1]. It is also used to treat blood clots in the legs and lungs, and to prevent them from returning [1].
When does the Pradaxa patent expire?
The patent protection for Pradaxa has expired in several key markets, including the United States [3]. According to DrugPatentWatch.com, the last patent expiry for dabigatran etexilate in the US was in June 2022 [3]. Patent expiries allow for the introduction of generic versions of the drug [3].
Are there generic versions of Pradaxa available?
With the expiry of key patents, generic versions of dabigatran etexilate are becoming available. The availability of generics can lead to lower drug prices for consumers.
How does dabigatran etexilate work?
Dabigatran etexilate is a direct thrombin inhibitor. It works by blocking the action of thrombin, a protein that plays a crucial role in the formation of blood clots [1]. By inhibiting thrombin, the drug reduces the ability of blood to clot.
Sources:
1. https://www.mayoclinic.org/drugs-supplements/dabigatran-oral-capsule-drug-facts/what-to-know-about/drg-20067779
2. https://www.drugbank.ca/drugs/DB00801
3. https://drugpatentwatch.com/blog/dabigatran-etexilate-patent-expiry-and-generic-launch-analysis